Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genertec Universal Medical Group CoFRA:5UM -0.41%48 5-Year Yield-on-Cost % is 9.42 as of Aug. 21, 2026, which is 50% above its 10-year median of 6.26. GuruFocus rates FRA:5UM with a GF Score™ of 48/100 and a GF Value™ of €0.48 (Fairly Valued). The stock has 5 warning signs investors should review. Among 210 Credit Services companies, Genertec Universal Medical Group Co ranks better than 80.95% on this metric.
Genertec Universal Medical Group Co (FRA:5UM) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Genertec Universal Medical Group Co 5-Year Yield-on-Cost % Related Terms
FRA:5UM vs V, MA, AXP: 5-Year Yield-on-Cost % Comparison
For the Credit Services subindustry, Genertec Universal Medical Group Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genertec Universal Medical Group Co 5-Year Yield-on-Cost % vs Credit Services Industry
For the Credit Services industry and Financial Services sector, Genertec Universal Medical Group Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Genertec Universal Medical Group Co's 5-Year Yield-on-Cost % falls into.
Genertec Universal Medical Group Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Genertec Universal Medical Group Co (FRA:5UM) has a 5-Year Yield-on-Cost % of 9.42 as of Aug. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Genertec Universal Medical Group Co and its competitors. This is 50% above median its historical median of 6.26. Over the past decade, Genertec Universal Medical Group Co's 5-Year Yield-on-Cost % has ranged from 1.76 to 10.58. According to the industry distribution chart, Genertec Universal Medical Group Co ranks #40 out of 210 companies in the Credit Services industry, placing it in the top 19%.
Is Genertec Universal Medical Group Co's 5-Year Yield-on-Cost % too high?
Genertec Universal Medical Group Co's current 5-Year Yield-on-Cost % of 9.42 is 50% above median its 10-year median of 6.26. Over the past 10 years, this metric has ranged from a low of 1.76 to a high of 10.58. The Credit Services industry median 5-Year Yield-on-Cost % is 4.52. Genertec Universal Medical Group Co's value of 9.42 is 108.4% above this industry median. Based on the distribution chart, Genertec Universal Medical Group Co ranks #40 out of 210 companies in the Credit Services industry, which is in the top quartile — a strong position relative to peers. Overall, Genertec Universal Medical Group Co has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genertec Universal Medical Group Co's 5-Year Yield-on-Cost % compare to V and MA?
According to the Credit Services industry distribution chart, Genertec Universal Medical Group Co ranks #40 out of 210 companies for 5-Year Yield-on-Cost %. This places Genertec Universal Medical Group Co in the top 19% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 4.52. Genertec Universal Medical Group Co's value of 9.42 is 108.4% above this benchmark. Historically, Genertec Universal Medical Group Co's own 5-Year Yield-on-Cost % has ranged from 1.76 to 10.58 over the past decade. While the company's 10-year median is 6.26 vs. the industry median of 4.52, Genertec Universal Medical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Credit Services company?
The median 5-Year Yield-on-Cost % among Credit Services companies is 4.52, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genertec Universal Medical Group Co's current 5-Year Yield-on-Cost % of 9.42 is 108.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Genertec Universal Medical Group Co and its competitors. For the Credit Services industry, the median 5-Year Yield-on-Cost % is 4.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genertec Universal Medical Group Co's current 5-Year Yield-on-Cost % is 9.42, which is 50% above median its own 10-year median of 6.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genertec Universal Medical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co (FRA:5UM) is currently considered Fairly Valued. The stock's GF Value™ is €0.48, compared to a current price of €0.48 — trading 0.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 9.42, which is 50% above median its 10-year median of 6.26 and 108.4% above the Credit Services industry median of 4.52. Genertec Universal Medical Group Co's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Genertec Universal Medical Group Co (FRA:5UM), the current 5-Year Yield-on-Cost % is 9.42 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genertec Universal Medical Group Co (FRA:5UM) Overvalued in 2026?
Based on GuruFocus' analysis, Genertec Universal Medical Group Co stock appears to be overvalued.
The current stock price of €0.48 is trading 0.4% above its estimated GF Value™ of €0.48.
GuruFocus considers Genertec Universal Medical Group Co to be Fairly Valued.
Key valuation signals for FRA:5UM:
5-Year Yield-on-Cost %: 9.42 (50% above median its 10-year median of 6.26)
GF Value™: €0.48 vs. price of €0.48 (0.4% above fair value)
Industry Position: 108.4% above the Credit Services median (#40 of 210)
No single metric tells the full story. See the FRA:5UM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genertec Universal Medical Group Co Ltd is principally engaged in providing financing to its customers under finance lease arrangements, the provision of advisory services, the sale of medical equipment as well as leases under operating lease arrangements, and the provision of other services. The group has two business segments namely The finance business comprises direct finance leasing, sale-and-leaseback, factoring, operating leases, and advisory services; and Healthcare business comprises includes hospital group business, healthcare technology business and specialty business. Geographically, it derives a majority of its revenue from Mainland China.
48GF Score
Get the complete analysis for FRA:5UM
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5UM has been successfully added to your 
